Jul 13, 2021
Immutep Quarterly Activities Report
Jul 05, 2021
Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC
Jun 21, 2021
Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings
Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy
Jun 07, 2021
Immutep Reveals a New anti-LAG-3 Research Program
